Farmas USA

• First participants enrolled in Phase 1 portion of clinical trial of NVX‑CoV2373
• Preliminary immunogenicity and safety results expected in July 2020
• Phase 2 portion to begin promptly following successful Phase 1 results

NIH Study Supports Wide Use Of Gilead's Remdesivir In COVID-19

• The largest subgroup, those on a modest amount of supplemental oxygen, drove the favorable results.
• Positive trends in the primary and key secondary endpoint were seen in all subgroups except those already on mechanical ventilation.
• Mortality data trended strongly positive though not quite making statistical significance, but in the largest subgroup, mortality trends were quite favorable.
• Safety data was impressive; thus the NEJM and NIH are pointing to RDV as standard of care for all patients in hospital with pulmonary manifestations of COVID-19.

Full results from a clinical trial of the antiviral remdesivir are in: People with Covid-19 randomized to get the drug recovered in 11 days, compared to 15 for those on placebo, and were slightly less likely to die (7.1% compared to 11.9%)  https://t.co/pvvgyrjlaW

The Remdesivir Study Is Finally Out: Drug Only Helped Those On Oxygen, Finds Mortality Too High For Standalone Treatment